Pancreatic Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.
|
31227505 |
2019 |
Pancreatic Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
PCR-based-SafeSeqS assays were used to identify mutations at codon 12, 13 and 61 of KRAS in the primary pancreatic tumor and to detect ctDNA.
|
31250894 |
2019 |
Pancreatic Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Overall, the repurposing of decitabine emerged as an intriguing option for treating pancreatic tumors that are addicted to mutant KRAS, thus offering opportunities for improving the arsenal of therapeutics for this extremely deadly disease.
|
31492820 |
2019 |
Pancreatic Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
ERK1/2 inhibitor can suppress growth of KRAS-mutant pancreatic tumors by targeting cancer cell.
|
31133044 |
2019 |
Pancreatic Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets.
|
28778964 |
2018 |
Pancreatic Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
V‑Ki‑ras 2 Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the most important genes involved in pancreatic neoplasms, and exhibits a high mutation rate in pancreatic ductal adenocarcinomas and pancreatic intraepithelial neoplasia.
|
29658583 |
2018 |
Pancreatic Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Loss of IKBKE inhibits the initiation and progression of pancreatic tumors in mice carrying pancreatic-specific KRAS activation.
|
28069799 |
2017 |
Pancreatic Neoplasm
|
0.700 |
Biomarker
|
disease |
CTD_human |
The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.
|
25961927 |
2016 |
Pancreatic Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth.
|
27322423 |
2016 |
Pancreatic Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We disrupted Acvr1b specifically in pancreata of mice (Acvr1b(flox/flox);Pdx1-Cre mice) and crossed them with LSL-KRAS(G12D) mice, which express an activated form of KRAS and develop spontaneous pancreatic tumors.
|
26408346 |
2016 |
Pancreatic Neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Stat3, Il6st (encodes gp130), or Trp53 were disrupted, or a mutant form of P53 (P53R172H) or transgenic sgp130 were expressed, in mice that developed pancreatic tumors resulting from expression of activated KRAS (KrasG12D, KC mice).
|
27003603 |
2016 |
Pancreatic Neoplasm
|
0.700 |
Biomarker
|
disease |
CTD_human |
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.
|
26390243 |
2015 |
Pancreatic Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
|
25683115 |
2015 |
Pancreatic Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
To evaluate potential differences at a molecular level between KRAS mutant tumors (MT) and KRAS wild-type (WT) pancreatic tumors and the biological and prognostic significance of different KRAS mutations.
|
26161927 |
2015 |
Pancreatic Neoplasm
|
0.700 |
Biomarker
|
disease |
CTD_human |
Embelin suppresses growth of human pancreatic cancer xenografts, and pancreatic cancer cells isolated from KrasG12D mice by inhibiting Akt and Sonic hedgehog pathways.
|
24694877 |
2014 |
Pancreatic Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Furthermore, we identified phosphorylated KRAS in a panel of primary human pancreatic tumors.
|
24371225 |
2014 |
Pancreatic Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
To evaluate its diagnostic efficacy, we performed BCL10 immunohistochemistry and evaluated molecular markers correlated to pancreatic tumor lineages (neuroendocrine markers and a mutation analysis of KRAS and GNAS) using samples from 126 pancreatic tumors (17 ACCs, 24 pancreatic ductal adenocarcinomas, 4 adenosquamous carcinomas, 9 intraductal papillary mucinous neoplasms, 10 mucinous cystic neoplasms, 44 neuroendocrine tumors, 9 serous cystic tumors and 10 solid-pseudopapillary neoplasms).
|
23530562 |
2013 |
Pancreatic Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutations are major factors involved in initiation and maintenance of pancreatic tumors.
|
23565280 |
2013 |
Pancreatic Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Roles for KRAS in pancreatic tumor development and progression.
|
23622131 |
2013 |
Pancreatic Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Eighty-seven genomic alterations were identified in the 23 pancreatic tumor FNAs (average, 3.8 genomic alterations per patient); and the most common genomic alterations were KRAS, TP53, CDKN2A/B, SMAD4, and PTEN.
|
23893923 |
2013 |
Pancreatic Neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Knock down of K-RAS resulted in impaired tumor growth in all pancreatic xenograft models tested, demonstrating that K-RAS expression is indeed required for tumor maintenance of K-RAS mutant pancreatic tumors.
|
22952903 |
2012 |
Pancreatic Neoplasm
|
0.700 |
Biomarker
|
disease |
CTD_human |
Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in premalignant lesions.
|
21699781 |
2011 |
Pancreatic Neoplasm
|
0.700 |
Biomarker
|
disease |
CTD_human |
Isolation of a chemical inhibitor against K-Ras-induced p53 suppression through natural compound screening.
|
19424582 |
2009 |
Pancreatic Neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Surprisingly, the three enhancers are active in four different pancreatic tumor cell lines that express either normal K-ras gene or mutant K-ras.
|
19254697 |
2009 |
Pancreatic Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Efforts to model pancreatic cancer in mice have focused on mimicking genetic changes found in the human disease, particularly the activating KRAS mutations that occur in pancreatic tumors and their putative precursors, pancreatic intraepithelial neoplasia (PanIN).
|
19028876 |
2008 |